Effect of the interleukin-6 receptor antagonist tocilizumab as an adjunct to primary percutaneous coronary intervention in ST elevation myocardial infarction
- Prosjektnummer
- 2016008
- Ansvarlig person
- Lars Gullestad
- Institusjon
- Oslo universitetssykehus HF
- Prosjektkategori
- Doktorgradsstipend
- Helsekategori
- Cardiovascular, Inflammatory and Immune System
- Forskningsaktivitet
- 6. Treatment Evaluation
Nei
Nei
Nei
Nei
Nei
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction.
J Am Coll Cardiol 2021 04 20;77(15):1845-1855.
PMID: 33858620 - Inngår i doktorgradsavhandlingen
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)
Open Heart. 2019 Oct 15;6(2):e001108. doi: 10.1136/openhrt-2019-001108. eCollection 2019.
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction
J Am Coll Cardiol. 2021 Apr 20;77(15):1845-1855. doi: 10.1016/j.jacc.2021.02.049.
Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial
EBioMedicine. 2022 Jun;80:104013. doi: 10.1016/j.ebiom.2022.104013. Epub 2022 Apr 30.
Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
Open Heart. 2023 Aug;10(2):e002301. doi: 10.1136/openhrt-2023-002301.
Rationale for the ASSAIL-MI trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI).
Open Heart 2019;6:e001108. https://doi.org/10.1136/openhrt-2019-001108
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients WIth Acute ST-Segment Elevation Myocardial Infarction
J Am Coll Cardiol. 2021 Apr, 77(15) 1845-1855. https://doi.org/10.1016/j.jacc.2021.02.049
Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial
eBioMedicine 2022;80:104013. https://doi.org/10.1016/j.ebiom.2022.104013
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevastion myocardial infarction (STEMI)
http://dx.doi.org/10.1136/openhrt-2019-001108
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI)
openheart, 2019
Acute ST-elevation Myocardial Infarction and Interleukin-6 Inhibition. Cardioprotection and Novel Therapeutic Strategies
- Disputert:
- november 2023
- Hovedveileder:
- Kaspar Broch
- Jan Erik Nordrehaug Prosjektdeltaker
- Terje Steigen Prosjektdeltaker
- Erik Qvigstad Prosjektdeltaker
- Sindre Woxholt Prosjektdeltaker
- Kapil Sharma Prosjektdeltaker
- Ingebjørg Seljeflot Prosjektdeltaker
- Nils Einar Kløw Prosjektdeltaker
- Anders Opdahl Prosjektdeltaker
- Eirik Skogvoll Prosjektdeltaker
- Knut Haakon Stensæth Prosjektdeltaker
- Ola Kleveland Prosjektdeltaker
- Brage Høyem Amundsen Prosjektdeltaker
- Jan Kristian Damås Prosjektdeltaker
- Anne Kristine Anstensrud Doktorgradsstipendiat (finansiert av denne bevilgning)
- Einar Hopp Prosjektdeltaker
- Thor Ueland Prosjektdeltaker
- Svend Aakhus Prosjektdeltaker
- Kaspar Broch Medveileder
- Bjørn Bendz Medveileder
- Pål Aukrust Medveileder
- Geir Øystein Andersen Prosjektdeltaker
- Rune Wiseth Prosjektdeltaker
- Lars Gullestad Prosjektleder
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport